Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.7554
-0.0289-3.68%
Pre-market: 1.140.3834+50.75%04:10 EDT
Volume:26.44M
Turnover:30.08M
Market Cap:12.49M
PE:-0.17
High:0.8094
Open:0.7990
Low:0.7432
Close:0.7843
52wk High:12.23
52wk Low:0.7432
Shares:16.54M
Float Shares:11.46M
Volume Ratio:77.43
T/O Rate:230.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-11.46
PE(LYR):-0.04

Loading ...

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

MT Newswires Live
·
10 hours ago

Tempest Secures Exclusive Option to License Clinical-Stage Cd7-Targeted Lentiviral in Vivo CAR-T Platform

THOMSON REUTERS
·
12 hours ago

Tempest Therapeutics Inc: Entered into an Exclusive Option Agreement with Hebei Senlang Biotechnology Co., Ltd

THOMSON REUTERS
·
12 hours ago

Tempest Therapeutics - no Grade 3 or Higher Cytokine Release Syndrome or Neurotoxicity as of Aug 25, 2026

THOMSON REUTERS
·
12 hours ago

Tempest Therapeutics announces $7.5M private placement

TIPRANKS
·
Sep 11

Tempest Therapeutics Prices $2.5 Million Private Placement at $0.81 Per Share

Reuters
·
Sep 11

Tempest Therapeutics Announces up to $7.5 Million Private Placement

THOMSON REUTERS
·
Sep 11

Tempest Therapeutics CEO to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 08

Tempest Therapeutics - Justin Trojanowski to Resign as Principal Financial Officer and Principal Accounting Officer Effective Sept 1 - SEC Filing

THOMSON REUTERS
·
Aug 25

Tempest Therapeutics - Appoints Nicholas Rossettos as CFO, Principal Financial and Accounting Officer Effective Sept 1, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 25

Tempest Therapeutics Names Nicholas Rossettos CFO, Replacing Justin Trojanowski

Reuters
·
Aug 25

Tempest Therapeutics - Files to Offer up to 8,910,579 Shares - SEC Filing

THOMSON REUTERS
·
Aug 22

Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of Required Votes

Reuters
·
Aug 19

Tempest Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Tempest Therapeutics Enters USD 50 Million Equity Purchase Deal with Lincoln Park Capital Fund

Reuters
·
Aug 14

Tempest Therapeutics - Enters $50 Mln Common Stock Purchase Agreement with Lincoln Park - SEC Filing

THOMSON REUTERS
·
Aug 14

Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Tempest Therapeutics Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Tempest Therapeutics Partners with Senlang Biotech to Advance Tpst-4003 in Vivo CAR-T into First-in-human Trial

Reuters
·
Jul 21

Tempest Announces Development Collaboration with Senlang Biotechnology for Tpst-4003, a Cd7-targeted Next-generation in Vivo CAR-T

THOMSON REUTERS
·
Jul 21